Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous iron products.

C A Johnson1, N A Mason, G R Bailie

  • 1University of Wisconsin School of Pharmacy, Madison, USA.

ANNA Journal
|April 25, 2000
PubMed
Summary

Intravenous iron supplements are effective for treating anemia in dialysis patients. Iron gluconate and iron sucrose offer safer alternatives to iron dextran, with a lower risk of hypersensitivity reactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular disease and differences between the sexes.

American family physician·2001
Same author

dSIR2 and dHDAC6: two novel, inhibitor-resistant deacetylases in Drosophila melanogaster.

Experimental cell research·2001
Same author

Frequency doubling perimetry using a liquid crystal display.

American journal of ophthalmology·2001
Same author

Operative management of neuromatous knee pain: patient selection and outcome.

Annals of plastic surgery·2001
Same author

Equal access to health care.

Canadian family physician Medecin de famille canadien·2001
Same author

Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis.

The Journal of biological chemistry·2001

Area of Science:

  • Nephrology
  • Hematology
  • Pharmacology

Background:

  • Anemia is a common complication in patients undergoing dialysis.
  • Intravenous iron administration is a standard treatment for dialysis-associated anemia.
  • Iron dextran has been widely used but carries a risk of adverse reactions.

Purpose of the Study:

  • To evaluate the safety and efficacy of alternative intravenous iron formulations.
  • To compare the hypersensitivity reaction rates between iron dextran and newer iron products.

Main Methods:

  • Review of clinical data on intravenous iron use in dialysis patients.
  • Analysis of reported hypersensitivity reactions associated with different iron formulations.

Main Results:

  • Intravenous iron is generally safe and effective for anemia in dialysis patients.
  • Iron dextran carries a small risk of severe anaphylactoid reactions.
  • Iron gluconate and iron sucrose demonstrate a lower incidence of hypersensitivity.

Conclusions:

  • Iron gluconate and iron sucrose are viable, safer alternatives to iron dextran.
  • These formulations provide effective treatment for dialysis-associated anemia with reduced hypersensitivity risk.

Related Experiment Videos